DOCTOR'S VIEW ARCHIVE
Rezulin Withdrawn From Market Warning
Rezulin is the brand name for a drug called troglitazone and has been used in patients with type II diabetes to help lower and control blood sugars that are not controlled by insulin or by other oral anti-diabetic medications.
Because of increasing numbers of reports of patients who were taking Rezulin that developed serious liver toxicity, the Federal Drug Administration (FDA) has requested that the manufacturer, Parke-Davis/Warner-Lambert, withdraw the drug from the market. Parke-Davis/Warner-Lambert has agreed to implement an immediate withdrawal program.
The actual announcement by the FDA follows. Please note especially the last paragraph which reads "Patients using Rezulin are urged to contact their physicians for information about alternative treatments. Patients should not discontinue taking Rezulin or other treatments for diabetes without discussing alternative therapies with their physicians."
-- Medical Editor, MedicineNet.com
March 21, 2000 WASHINGTON, D.C. --FDA today asked the manufacturer of Rezulin (troglitazone) - a drug used to treat type 2 diabetes mellitus - to remove the product from the market. The drug's manufacturer, Parke-Davis/Warner- Lambert, has agreed to FDA's request.
- Allergic Skin Disorders
- Bacterial Skin Diseases
- Bites and Infestations
- Diseases of Pigment
- Fungal Skin Diseases
- Medical Anatomy and Illustrations
- Noncancerous, Precancerous & Cancerous Tumors
- Oral Health Conditions
- Papules, Scales, Plaques and Eruptions
- Scalp, Hair and Nails
- Sexually Transmitted Diseases (STDs)
- Vascular, Lymphatic and Systemic Conditions
- Viral Skin Diseases
- Additional Skin Conditions